Gold Standard
Regenerative
For individuals exploring alternatives to surgery, stem cell therapy for knee pain is evaluated on a case-by-case basis. Candidacy is determined through medical review, including imaging and clinical history. Not all patients qualify.
Stem cell therapy for the knee is typically considered by patients experiencing:
Patients often explore this option when looking for alternatives to joint replacement or long-term pain management strategies.
For general background on how stem cells are used in orthopedic applications, see Mayo Clinic and Cleveland Clinic.
Not all cases are suitable for regenerative therapies. This approach may not be recommended for:
A proper evaluation is required to determine whether a patient is a candidate.
Patient history and imaging (such as MRI or X-rays) are reviewed to assess joint condition and determine candidacy.
If appropriate, a treatment approach is developed based on the individual case, including condition severity and medical background.
Regenerative cells are administered in a controlled clinical setting. The specifics of the protocol vary depending on the patient.
Recovery, mobility, and symptom changes are monitored over time.
Some patients choose to explore treatment options outside the United States due to:
This is often part of a broader category known as medical travel or cross-border care.
Not sure whether this applies to your case? Candidacy is determined by medical review of your history and imaging, not by a form. The consultation is complimentary.
See If You QualifyPatients exploring stem cell therapy for knee conditions often seek improvements in:
Addressing chronic knee pain that impacts quality of life
Improving flexibility and range of motion in the knee
Returning to normal daily activities and function
Outcomes vary depending on factors such as age, severity of degeneration, and overall health.
For additional context on ongoing research in regenerative medicine, see the National Institutes of Health.
Regenerative treatment for knee osteoarthritis is investigational. It is not approved by the U.S. Food and Drug Administration for this use, and it is still being studied in clinical trials rather than settled in clinical practice. Anyone considering it deserves a clear account of where the research currently stands.
A 2022 systematic review in Stem Cells International pooled 28 randomised controlled trials covering 1,494 patients who received mesenchymal stem cell injections for osteoarthritis. It found no statistically significant difference in adverse events between the treatment and control groups, and reported no serious adverse events.
The same authors described the overall body of evidence as generally low quality and said their findings should be generalised with caution. The trials differ in cell source, dose and protocol, which makes them difficult to compare, and follow-up beyond twelve months is limited. Published effect sizes for pain and function also vary considerably between reviews, and how much of the improvement is attributable to the cells themselves remains an open question in the literature.
What that means in practice: the safety signal so far is reassuring, but effectiveness is not established, and no honest account of this research can promise a result. Whether it is appropriate for you is a decision for a physician who has reviewed your history and imaging.
Sources: The Effectiveness and Safety of Mesenchymal Stem Cells in the Treatment of Osteoarthritis: A Systematic Review and Meta-analysis of 28 Randomized Controlled Trials, Stem Cells International, 2022. Contextual effects of mesenchymal stem cell injections for knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials, Frontiers in Medicine, 2025.
All medical treatments involve potential risks and limitations.
Stem cell therapy is still an evolving area of medicine, and results are not guaranteed. Patients should undergo proper evaluation and review all considerations before proceeding.
You can review regulatory considerations through the U.S. Food and Drug Administration.
The procedure itself is typically completed in a single visit, but timelines vary depending on the protocol and evaluation process.
Recovery varies by individual, though many patients resume normal activities within a short period.
Costs vary based on protocol, clinic, and patient needs. Evaluation is required before any estimate is provided.
Certain uses of stem cells are regulated, and patients should understand the difference between approved and investigational therapies.
Candidacy depends on medical history, imaging, and condition severity. Not all patients are eligible.
If you are exploring options for knee pain, arthritis, or joint degeneration, the first step is determining whether you qualify. Candidacy is based on medical evaluation, not assumptions.
Start Your Evaluation →Medically reviewed by Dr. Karla Chavira, MD, Regenerative Medicine Physician and CEO of CMCells (Cédula Profesional on file).
Last reviewed: July 2026